Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
4basebio PLC (4BB.L)
GBp525.00
+0.00 (+0.00%)
GB LSE Healthcare Biotechnology
Address
25 Norman Way CB24 5QE
Cambridge, GB
Cambridge, GB
CEO
Amy Jo Walker
Website
4basebio.com
IPO
2021-02-17
ISIN GB00BMCLYF79
Also trades on
Deutsche Börse · 88Q.DE (EUR)
Frankfurt Stock Exchange · 88Q.F (EUR)
London Stock Exchange · 4BB.L (GBp)
Description
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other international markets. Their comprehensive offerings encompass research kits, bulk enzymes, various other biological products, as well as crucial licensing and AVV manufacturing services. The company primarily caters to clients within the biotech, pharmaceutical, and contract development and manufacturing organization (CDMO) industries. Notably, the firm adopted its current name, 4basebio PLC, in July 2021, having previously been known as 4basebio UK Societas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp525.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.6K
Beta
0.87
Float Shares
5.68M
Free Float %
36.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +11.49% | -3.96% | -11.82% | -31.93% | -21.14% | -56.31% | -12.61% | +27.63% | +43.70% | +43.70% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
525.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.87
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+81.5% ★ Q4'25: +93.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-16.0% Q4'25: -78.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,018.5% Q4'25: -1,396.1% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-988.0% Q4'25: -1,637.0% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-189.8% Q4'25: -374.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+18.2% Q4'25: +26.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.06× Q4'25: -0.52× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
462.0K
est: 400.0K (+15.5%)
|
338.0K
est: 300.0K (+12.7%)
|
268.0K
est: 300.0K (-10.7%)
|
506.0K
est: 596.0K (-15.1%)
|
933.0K
est: 1.10M (-15.2%)
|
1.69M
est: 1.70M (-0.4%)
|
2.60M
2.60M – 2.60M
+52.9% YoY
|
15.00M
15.00M – 15.00M
+476.9% YoY
|
25.00M
25.00M – 25.00M
+66.7% YoY
|
35.00M
35.00M – 35.00M
+40.0% YoY
|
| EBITDA |
-346.0K
est: -379.9K (+8.9%)
|
-3.21M
est: -284.9K (-1,025.5%)
|
-5.41M
est: -284.9K (-1,798.3%)
|
-7.34M
est: -596.0K (-1,132.0%)
|
-10.97M
est: -1.10M (-897.2%)
|
-15.58M
est: -1.70M (-816.6%)
|
-2.60M
-2.60M – -2.60M
-52.9% YoY
|
-15.00M
-15.00M – -15.00M
-476.9% YoY
|
-25.00M
-25.00M – -25.00M
-66.7% YoY
|
-35.00M
-35.00M – -35.00M
-40.0% YoY
|
| EBIT |
-622.0K
est: -400.0K (-55.5%)
|
-3.53M
est: -300.0K (-1,075.7%)
|
-5.84M
est: -300.0K (-1,846.7%)
|
-8.05M
est: -596.0K (-1,251.0%)
|
-11.90M
est: -1.10M (-982.0%)
|
-16.73M
est: -1.70M (-883.9%)
|
-2.60M
-2.60M – -2.60M
-52.9% YoY
|
-15.00M
-15.00M – -15.00M
-476.9% YoY
|
-25.00M
-25.00M – -25.00M
-66.7% YoY
|
-35.00M
-35.00M – -35.00M
-40.0% YoY
|
| Net Income |
-719.0K
est: -1.55M (+53.5%)
|
-3.24M
est: -3.53M (+8.3%)
|
-5.15M
est: -5.39M (+4.5%)
|
-7.67M
est: -12.19M (+37.1%)
|
-12.33M
est: -13.50M (+8.6%)
|
-16.91M
est: -17.06M (+0.9%)
|
-15.51M
-15.51M – -15.51M
+9.1% YoY
|
-12.10M
-12.10M – -12.10M
+22.0% YoY
|
-7.75M
-7.75M – -7.75M
+35.9% YoY
|
-4.65M
-4.65M – -4.65M
+40.0% YoY
|
| SGA |
657.0K
est: 1.83M (-64.1%)
|
1.86M
est: 1.37M (+35.2%)
|
2.96M
est: 1.37M (+115.3%)
|
1.54M
est: 3.77M (-59.1%)
|
1.77M
est: 6.97M (-74.7%)
|
17.28M
est: 10.77M (+60.4%)
|
16.47M
16.47M – 16.47M
+52.9% YoY
|
95.00M
95.00M – 95.00M
+476.9% YoY
|
158.33M
158.33M – 158.33M
+66.7% YoY
|
221.67M
221.67M – 221.67M
+40.0% YoY
|
| EPS |
-0.06
est: -0.12 (+50.5%)
|
-0.26
est: -0.27 (+3.3%)
|
-0.42
est: -0.41 (-2.2%)
|
-0.62
est: -0.79 (+21.1%)
|
-0.94
est: -0.87 (-8.0%)
|
-1.09
est: -1.10 (+0.9%)
|
-1.00
-1.00 – -1.00
+9.1% YoY
|
-0.78
-0.78 – -0.78
+22.0% YoY
|
-0.50
-0.50 – -0.50
+35.9% YoY
|
-0.30
-0.30 – -0.30
+40.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-17.04M
OE per share TTM
-1.20
Owner's Yield
-22.61%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
466.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-1.7K
Shares Outstanding
15.48M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amy Walker | CEO & Director | 308.0K | female |
| Christine Wolosin | Chief Commercial Officer | — | female |
| Jennifer Gelman | Vice President of Marketing | — | female |
| Manja Hermina Elisabeth Maria Boerman | Executive Chair of the Board | — | — |
| Scott Lorimer | Chief Operating Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4BB.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
